DHT – Dihydrotestosterone
Dihydrotestosterone (DHT) is an androgen, synthesized primarily in the male prostate gland, testes, hair follicles, and adrenal glands by the enzyme 5a-reductase. DHT has an important role in optimizing your over-all health and performance via the central nervous system, increasing strength, fighting against stress, and improving sexual function and libido.
A study was conducted in Finland to investigate the effects of dihydrotestosterone (DHT) gel on general well-being, sexual function, and the prostate in aging men. 120 men participated in this randomized, placebo-controlled study (60 DHT and 60 placebo) with 114 completing it.
DHT gel was administered transdermally for 6 months, with the dose varied from 125–250 mg/d.
Results were evaluated using a questionnaire, and prostate symptoms were evaluated using the International Prostate Symptoms Score, transrectal ultrasonography, and assay of serum prostate-specific antigen.
Early morning erections improved in the DHT group at 3 months of treatment, and the ability to maintain erection also improved in the DHT group. No significant changes were observed in general well-being between the placebo and the DHT group. Prostate weight and prostate-specific antigen levels did not change during the treatment. No major adverse events were observed.
Topical DHT gel improves sexual function and may be a useful alternative to aromatizing androgens in the treatment of aging men requiring androgen replacement.
The effects of dihydrotestosterone (DHT) on prostate growth are not yet completely understood, and research is on-going. Short-term studies using transdermal Andractim DHT gel have indicated that DHT could prevent prostate growth and may be beneficial to overall prostate health.
Long-term results seem to tell a different story however. In a new study published November 16 in the Annals of Internal Medicine, researchers confirmed that 2 years of treatment with DHT gel showed no benefit over placebo at reducing prostatic growth.
Background: Benign prostatic hypertrophy increases with age and can result in substantially decreased quality of life for older men. Surgery is often required to control symptoms. It has been hypothesized that long-term administration of a nonamplifiable pure androgen might decrease prostate growth, thereby decreasing or delaying the need for surgical intervention. ‘
Participants: Healthy men (n = 114) older than 50 years without known prostate disease.
Intervention: Transdermal DHT (70 mg) or placebo gel daily for 2 years.
Results: Over 24 months, there was an increase in total (29% [95% CI, 23% to 34%]) and central (75% [CI, 64% to 86%]; P < 0.01) prostate volume and serum prostate-specific antigen level (15% [CI, 6% to 24%]) with time on study, but DHT had no effect (P > 0.2). Dihydrotestosterone treatment decreased spinal BMD (1.4% [CI, 0.6% to 2.3%]; P < 0.001) at 24 months but not hip BMD (P > 0.2) and increased serum aminoterminal propeptide of type I procollagen in the second year of the study compared with placebo. Dihydrotestosterone increased serum DHT levels and its metabolites (5α-androstane-3α,17β-diol and 5α-androstane-3β,17β-diol) and suppressed serum testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone levels. Dihydrotestosterone increased hemoglobin levels (7% [CI, 5% to 9%]), serum creatinine levels (9% [CI, 5% to 11%]), and lean mass (2.4% [CI, 1.6% to 3.1%) but decreased fat mass (5.2% [CI, 2.6% to 7.7%]) (P <0.001 for all). Protocol-specific discontinuations due to DHT were asymptomatic increased hematocrit (n = 8), which resolved after stopping treatment, and increased prostate-specific antigen levels (n = 3; none with prostate cancer) in the DHT group. No serious adverse effects due to DHT occurred.
Conclusion: Dihydrotestosterone treatment for 24 months has no beneficial or adverse effect on prostate growth but causes a decrease in spinal but not hip BMD. These findings have important implications for the wider use of nonsteroidal pure androgens in older men.
Note that “no serious adverse effects due to DHT occurred,” indicating that using DHT for this length of time is relatively safe.
Are you taking DHT blockers to prevent hair loss? If so, you may be increasing your risk for developing prostate cancer, as well as sexual dysfunction.
A study by the Cochrane Review found that 5-alpha-reductase inhibitors—drugs and supplements that prevent the conversion of testosterone to dihydrotestosterone (DHT)—have inadequate evidence to say they reduce mortality, in terms of prostate cancer. While abnormally elevated levels of DHT may increase male patients’ risks of developing prostate cancer, a metabolite of DHT, 3-beta-adiol, may actually help prevent and reduce the grade of prostate cancers. The production of the this important metabolite, 3-beta-adiol, is reduced by 5-alpha-reductase inhibitors.
Some researchers in the Prostate Cancer Prevention Trial (PCPT), after reviewing the results of this 7 year study, feel that while DHT levels are important, levels of 3-beta-adiol are also important. Further, the clinical experience of Dr. Jonathan Wright, MD—the father of bio-identical hormone replacement therapy—have provided evidence that the ratio of DHT to 3-beta-adiol may be more important than the amount of DHT alone.
There’s a lot of confusion out there about DHT and the prostate gland. The truth is that the effects of DHT on the prostate are not clearly known. In fact, research indicates that DHT can actually help shrink the prostate and that topical DHT may be beneficial for some men at preventing benign prostatic hyperplasia, or BPH.
A study done with rats revealed more interesting data about DHT. Researchers challenged the notion that dihydrotestosterone is the active trophic androgen in initiating pathogenic changes in the prostate gland. Groups of prostate cancer-susceptible male rats were treated with subcutaneous depots of testosterone or of DHT. After 14 months, prostate adenocarcinomas had developed in 24% of the testosterone-treated rats but not in the DHT-treated rats. It appears that DHT is a key contributor to the prevention of prostate problems and could be beneficial to overall prostate health.
Dihydrotestosterone is often used in research settings when studying androgenic hormones because it’s a potent, non-aromatizable androgen receptor agonist. Meaning, not only is DHT strong, it also doesn’t convert to estriadol and it binds to androgen receptors and triggers a response.
Researchers in Oregon conducted a study with rainbow trout to test antiestrogenic responses. DHT and two weak, aromatizable androgens, DHEA and androstenedione, were fed to juvenile trout for 2 weeks. Results showed that DHEA and androstenedione significantly increased blood plasma vitellogenin (Vg) by up to 30- and 45-fold, respectively, and 17β-Estradiol (E2) increases were also observed with both androgens. DHT on the other hand, caused a marked decrease in Vg and E2 levels, suggesting that DHEA and androstenedione increased Vg and E2 via conversion to estriadol (not by estrogen receptor agonism.) Read the full abstract here.
The results are particularly relevant to sufferers of Gynecomastia because they strengthen the case for DHT gel treatment. Gynecomastia is the result of hormonal imbalances, and topically applied DHT gel restores balance by increasing DHT levels and decreasing testicular estriadol and testosterone secretion. Studies have shown that DHT gel causes dramatic reductions in Gynecomastia within 10-21 days.
If you suffer from Gynecomastia, you owe it to yourself to look into DHT gel treatment. It’s a safe, effective and affordable way to get rid of “man boobs” and restore a masculine chest.